COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 1, Open-Label, Study Of Voruciclib In Subjects With Relapsed And/Or Refractory B Cell Malignancies Or Acute Myeloid Leukemia After Failure Of Prior Standard Therapies

Protocol No
MEI-ME-522-001
Principal Investigator
Sameem Abedin
Phase
I
Summary
Voruciclib blocks a molecule called cyclin-dependent Kinase (CDK), which then decreases the amount of another molecule, called myeloid cell leukemia protein 1 (Mcl-1). Mcl-1 shows up in large amounts in B cell type cancers. It is thought that blocking Mcl-1may stop the growth of B cell type cancers or enable other drugs to work more effectively.
Description
This project is being done to determine the highest safely tolerated dose of voruciclib in patients that have relapsed and/or refractory B cell type cancers or acute myeloid leukemia.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL